Drugs / Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
Cell therapy targets CD19, CD22 via depletion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03468153 | Jan 2018 → Jan 2019 | lymphoma | Ruijin Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03468153 ↗ |
| Action | Deplete | “The CAR enables the T-cells to recognize and kill the tumor cell through recognition of CD19 and CD22” NCT03468153 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor-modified T cell (CART) therapy” NCT03468153 ↗ |
| Target | CD19 | “through recognition of CD19 and CD22” NCT03468153 ↗ |
| Target | CD22 | “through recognition of CD19 and CD22” NCT03468153 ↗ |